Resmed and Astral devices faced cost increases and required a $42 million charge, impacting operating margins, according to analysts.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Resmed and Astral devices faced cost increases and required a $42 million charge, impacting operating margins, according to analysts.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Goldman Sachs
American investment bank
-
Resmed
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions